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Background: Dermatophytes are the main causative agent of all onychomycosis, but genus
Microsporum  is infrequent and the risk of acquiring the infection is often associated with
exposure  to risk factors.
Objectives:  To describe clinical characteristics of onychomycosis due to Microsporum ony-
chomycosis  in an urban population.
Methods:  This was a retrospective analysis of the epidemiological and clinical features of
18 Microsporum onychomycosis cases of a total of 4220 of onychomycosis cases diagnosed
between  May 2008 and September 2011 at the tertiary referral center for mycology in
Guatemala.
Results:  Eighteen cases of Microsporum onychomycosis (M. canis, n = 10; M. gypseum, n = 7; M.
nanum,  n = 1) were identiﬁed (prevalence = 0.43%). Infection was limited to nails only and
disease  duration ranged from 1 month to 20 years (mean = 6.55 years). The toenails were
affected  in all cases except for a single M. gypseum case of ﬁngernail. The most common
clinical  presentation was distal lateral subungual onychomycosis (12/18) followed by total
dystrophic  onychomycosis (5/18), and superﬁcial white onychomycosis (1/18). M. gypseum
presented  in 6 cases as distal lateral subungual onychomycosis and in 1 case like total
dystrophic  onychomycosis. Five cases (27.78%) were associated with hypertension, diabetes,
and  psoriasis. Treatment with terbinaﬁne or itraconazole was effective. Two cases of M. canis
distal lateral subungual onychomycosis responded to photodynamic therapy.
Conclusion: This is the largest reported series of Microsporum onychomycosis and demon-
strates  such a disease in an urban population. In 27.78% of the cases risk factors for infectionwere  associated to comorbid states. We  also report the ﬁrst 2 cases of successfully treated
M.  canis onychomycosis with photodynamic therapy and a rare case of M. canis associated
dermatophytoma. This study was  realized in the “Unidad de Micología Médica” of the
ordero C.” Guatemala City, Guatemala.
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tion: eight males and 10 females were affected. M. canis
affected both men  (4/10) and women (6/10) as did M. gyp-
seum  (four males and three females affected) and M.  nanum182  b r a z j i n f e c t d 
Introduction
Onychomycosis is the commonest nail disease worldwide
accounting for 50% of all nail disorders in some studies.1,2
Although it is not a fatal infection it can be associated with
discomfort and negative self-image3 and can predispose to
soft  tissue infection, particularly cellulitis.4 Toenails are pre-
dominantly  affected and the major risk factor is occlusive
footwear. Consequently, the prevalence of infection is often
higher  in urbanized populations. Fingernail infection, which
is  less common, is usually associated with occupational expo-
sure  to wet-work. Nail diseases such as psoriasis or damage to
the nail plate also predispose to infection as do comorbidities,
particularly diabetes mellitus, peripheral arterial disease, and
HIV  infection. Patients may  have more  than a single risk fac-
tor  for infection. The incidence of onychomycosis is rising as a
result of increasing exposure to risk factors and predisposing
comorbid states.5,6
Onychomycosis is caused by dermatophytes, yeasts, and
non-dermatophyte molds. Dermatophytes are the main
causative agent in temperate climates and account for 90%
of  toenail infections and at least 50% of ﬁngernail infections.
Trichophyton rubrum is the commonest isolated dermatophyte
and  is responsible for the majority of cases of toenail infection,
followed  by T. mentagrophytes and Epidermophyton ﬂoccosum.
Fingernail onychomycosis is more  commonly associated with
yeast  infection, particularly Candida. Epidemiological studies
from  the Tropics and regions with high humidity sometimes
report  a higher prevalence of non-dermatophyte infection for
both toenail and ﬁngernail onychomycosis. T. tonsurans has
occasionally  been associated with onychomycosis but M. canis,
M. gypseum and M.  nanum are extremely rare etiological agents
and  the risk of acquiring Microsporum infection is often associ-
ated  with a history of exposure and presence of risk factors.6,7
We  have observed an increasing prevalence of onycomy-
cosis  in Guatemala. We presume this is due to urbanization
which is associated with risk factors for onychomycosis. We
have  also noticed several cases of Microsporum onychomycosis
in  a relatively short period of time and the aim of this study
was  to deﬁne the disease characteristics of Microsporum nail
infection  within our cohort, its clinical course, and any risk
factors  for infection.
Materials  and  methods
This is a retrospective study conducted at a tertiary refer-
ral  center for mycology at the “Instituto de Dermatología y
Cirugía  de Piel Prof. Dr Fernando A. Cordero C.” in Guatemala
City,  Guatemala. Eighteen cases of mycologically proven ony-
chomycosis were  identiﬁed between May  2008 and September
2011.  The diagnosis of onychomycosis was  conﬁrmed by direct
microscopy  using 10% potassium hydroxide and cultured
using  Sabouraud dextrose agar with chloramphenicol. Fol-
lowing  mycological conﬁrmation patients were  treated with
standard  drug therapy regimens. Three-month courses of
either  daily oral terbinaﬁne (250 mg  daily) or pulse itracona-
zole  (200 mg  twice daily for one week every month) were
most  commonly used. Oral ﬂuconazole was  sometimes given
at  a weekly dosage of 300 mg  as it is a low cost and more 1 4;1  8(2):181–186
affordable option for some patients. Two patients with M.
canis  distal lateral subungual onychomycosis (DLSO) aged 66
and  74 years were treated with photodynamic therapy (PDT)
using  5-aminolevulinic acid (ALA) as PDT is not known to
have  any adverse systemic effects. Both patients received a
maximum of four PDT sessions given at weekly intervals at
a  wavelength of 630 nm at 57.6 J/cm2 using a light-emitting
diode (LED) PDT with red light. Clinical cure was  veriﬁed by
conﬁrming  mycological cure. Any atypical cases of onychomy-
cosis  were investigated for underlying HIV infection or other
causes  of immunosuppression, including long-term immuno-
suppressant drug therapy. A history of medical risk factors
and  occupational exposure was sought. Epidemiological and
clinical  data were collected for all cases of Microsporum ony-
chomycosis. The study did not require an approval from the
Ethics  Committee.
Results
A total of 4220 cases of mycologically proven onychomycosis
were identiﬁed during a period of 41 months between May
2008  and September 2011. Eighteen of these cases were of the
genus  Microsporum, representing 0.43% of the total number of
onychomycosis  cases (18/4220). The majority of the rest of the
cases  were  due to T. rubrum. Table 1 summarizes all character-
istics  of patients with Microsporum onychomycosis.
All the Microsporum cases were positive on culture and 17
of  18 of them were  also positive on direct microscopy. Inter-
estingly,  direct microscopy of a case subsequently conﬁrmed
on  culture as M.  canis demonstrated dermatophytoma. Ten
of  the 18 cases were due to M.  canis (prevalence 0.24%), the
other  seven were due to M. gypseum (prevalence 0.17%), and
the  remaining case was due to M. nanum (0.024%) (Figs. 1 and 2).
There  was no signiﬁcant difference in gender distribu-Fig. 1 – Culture of Microsporum nanum on Sabouraud
dextrose agar with chloramphenicol.
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Table 1 – Characteristics of patients with Microsporum onychomycosis.
Case Sex Age
(years)
Clinical
subtype
Disease
duration
(years)
Direct
microscopy
Culture  HIV status Comorbidities Treatment Response to
treatment
1 F 25 DLSO 1/4 Hyphae M. gypseum Neg No Itraconazole No follow-up
2 F 48 DLSO 14 Dermato-
phytoma
M.  canis Neg HT, DM Flucoanzole,
itraconazole
Cure
3  M 42 TDO 1 Hyphae M. canis Neg No Itraconazole No follow-up
4 M 49 WSO 10 Hyphae M. canis Neg No Itraconazole No follow-up
5 M 74 TDO 4 Negative M. canis Not tested HT Terbinaﬁne Cure
6 M 24 DLSO 12 Hyphae M. gypseum Not tested No Itraconazole No follow-up
7 F 74 DLSO 5 Hyphae M. canis Neg HT PDT Cure
8 F 66 DLSO 1/2 Hyphae M. canis Neg HT PDT Cure
9 M 32 DLSO 15 Hyphae M. gypseum Neg Psoriasis Itraconazole No follow-up
10 F 8 DLSO 1/2 Hyphae M. canis No tested No Terbinaﬁne Cure
11 M 61 DLSO 1/12 Spores M. canis No tested No Itraconazole No follow-up
12 F 52 DLSO 7 Spores M. canis No tested No Fluconazole
and timole
No  follow-up
13 M 29 DLSO 1/2 Hyphae M. gypseum No tested No Terbinaﬁne Cure
14 F 49 TDO 20 Hyphae M. canis Not tested No Terbinaﬁne Cure
15 M 18 DLSO 3 Hyphae M. gypseum Not tested No Terbinaﬁne No follow-up
16 F 61 TDO 10 Hyphae M. gypseum No tested No Terbinaﬁne No follow-up
17 F 38 DLSO 10 Hyphae M. gypseum No tested No Terbinaﬁne No follow-up
18 F 35 TDO 5 Hyphae
and Spores
M.  nanum No tested No Itraconazole Cure
DM, diabetes mellitus; DLSO, distal lateral subungual onychomycosis; F, fe
therapy; TDO, total dystrophic onychomycosis; WSO, white subungueal on
Fig. 2 – Microsporum nanum macroconidia on lactophenol
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care  with disease duration of one year or less, one of them
had  M. gypseum onychomycosis. The others had suffered from
onychomycosis for many  years. None of the patients had tinealue  stain. 40×.
one female affected). Seventeen cases were adult patients
nd  one case was  a boy patient. M.  canis affected a group
f  people with an age range of 8–74 years (mean 52.3 years);
.  gypseum, an age range of 18–61 years (mean 32.43 years),
nd  M.  nanum affected only one person. All patients had
oenail  onychomycosis except for one patient with M.  gyp-
eum  onychomycosis affecting a single ﬁngernail, who was  a
oung man  with a twelve-year history of nail infection butmale; HT, hypertension; M, male; Neg, negative; PDT, photodynamic
ychomycosis.
with  no predisposing risk factors for onychomycosis (case 6
in Table 1). The most common clinical presentation was  DLSO
(12/18)  followed by total dystrophic onychomycosis (TDO, 5/18)
and superﬁcial white onychomycosis (SWO, 1/18). M.  gypseum
presented  mostly as DLSO (6/7) whereas M. canis had varied
clinical  presentations and M.  nanum only presented as TDO
(1/18)  (Fig. 3).
The  duration of Microsporum onychomycosis prior to pre-
sentation  at our Institute varied widely, from one month to 20
years  (mean 6.55 years). Only three patients sought medicalFig. 3 – Total dystrophic onychomycosis due to Microsporum
nanum.
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affecting other parts of their body such as tinea corporis or tinea
capitis.  Seven of the 18 patients were  screened for HIV infection
and  were found to be negative. The 11 patients who were not
tested  for HIV did not display any signs of immunodeﬁciency.
None of the patients had any other cause of immunodeﬁ-
ciency nor had they been on any immunosuppressant therapy.
They  did not have current or prior contact with domestic
cats and dogs. Although in Guatemala households commonly
keep  animals close contact with animals is unusual and was
not  reported by any of our patients. Four patients suffered
from  hypertension, one of them also had diabetes mellitus.
Our  patients with hypertension had not been investigated for
peripheral arterial disease, which is a signiﬁcant risk factor
for  onychomycosis, although both conditions are known to be
strongly associated. A single patient suffered from psoriasis,
which  affects both skin and nails.
Treatment responses were  generally good, although we
were  not able to conﬁrm mycological cure in some patients
who  failed to return for follow-up. Only a single patient in our
cohort  with a 14-year history of M. canis DLSO and an asso-
ciated  dermatophytoma was  treated with oral ﬂuconazole.
She  failed to respond after six months of weekly ﬂucona-
zole  therapy, but subsequently demonstrated both clinical and
mycological  cure following three months of pulse itraconazole
therapy. Pulse itraconazole was  given to seven other patients,
including  the three patients with M. gypseum, three further
cases  of M. canis, and one case of M.  nanum. Two cases of
M.  canis and one case of M. gypseum treated with terbinaﬁne
demonstrated clinical and mycological cure as did the two
cases  of M.  canis DLSO treated with a total of four sessions
of  PDT each.
Discussion
Microsporum sp. as an infrequent agent of onychomycosis is.
Our  study of a Central American urban population demon-
strated  a prevalence of only 0.43% for M. canis, M.  gypseum,
and  M.  nanum nail infection. There are few recent comparative
studies  describing case series of Microsporum onychomycosis.
An  early study of onychomycosis from Mexico identiﬁed a
prevalence  of 3% of M.  canis infection (of 733 onychomyco-
sis cases).8 In Turkey, M. canis onychomycosis was  identiﬁed
in  8% of cases (6/73).9 Another study in 375 patents with
onychomycosis in Taiwan seven cases of Microsporum ony-
chomycosis  were  found (M. ferrugineum, n = 5; M. nanum, n = 2),
representing 1.87% of the causative pathogens in that pop-
ulation.  M. gypseum as a cause of any dermatophytosis is
much  less common than M. canis. Studies from Spain and
Italy  have found M.  gypseum prevalence of 1.5–5.2% among all
cases  of dermatophytoses.10,11 However, a recent study of ony-
chomycosis  in rural farmers in Nigeria revealed a prevalence
of  11.6% of M.  gypseum DLSO (eight cases out of a total of 261
cases  of onychomycosis) but no cases of M. canis infection.12
This high prevalence of M gypseum onychomycosis in this
particular  population is probably attributable to occupational
exposure to soil as M.  gypseum is a geophillic dermatophyte.
Although these studies appear to demonstrate much  higher
prevalence  for Microsporum onychomycosis, their sample sizes
were smaller than ours. 1 4;1  8(2):181–186
The prevalence of onychomycosis varies throughout the
world  and risk factors for its development include the use
of  occlusive footwear in urban populations and high levels
of  environmental humidity. Our patient population fulﬁlls
both  of these categories and consequently we  see large num-
bers  of patients with onychomycosis. In addition, signiﬁcantly
higher  levels of onychomycosis have been reported in pedi-
atric  populations in both Guatemala as well as in neighboring
Mexico compared with other more  temperate regions of the
world.13
The genus Microsporum is distributed worldwide and M.
canis  is the most common zoophillic species to affect humans,
primarily  causing tinea capitis in children. Domestic dogs and
cats  are usually the reservoir of infection and are often healthy
carriers  of Microsporum. In adults, unusual clinical presenta-
tions  of M. canis infection have been described such as severe
and  inﬂammatory tinea barbae and very atypical tinea faciei,14
and M.  canis infection in adults has often been associated
with immnosuppressive states.15 Patients with M.  canis ony-
chomycosis may  also report owning domestic cats or dogs and
sometimes  they have concomitant M. canis tinea corporis or
tinea  capitis which can occur from autoinoculation.16–19 M.
canis  onychomycosis has also been reported in association
with  HIV infection15 and long-term immunosupressant drug
therapy18 M. gypseum is a soil saprophyte and the source of
human  infection has been traced to soil, dogs and cats.20 Other
than  occupational exposure as described in the report of high
levels  of infection among rural Nigerian farmers,12 the rising
incidence  of M. gypseum infections may be attributable to the
domestication  of dogs and cats, which causes soil contamina-
tion  and increases the risk of infection to humans. It has also
been  suggested that M.  gypseum may  be undergoing phyloge-
netic  evolution from a geophillic saprophyte to a human and
animal  parasite.21 The most frequent clinical presentation of
M.  gypseum infection is tinea corporis on exposed areas of the
body  followed by tinea capitis, which is sometimes associated
with  kerion formation.
The  clinical subtypes of onychomycosis seen in our study
correlate  with previously reported studies of nail infection
with  Microsporum sp. with DLSO being the most common
clinical presentation followed by TDO and SWO, and rarely
PSO.17–19 All our cases of M.  gypseum infection presented as
DLSO.  This is the main clinical subtype described in ear-
lier  studies22,23 although there is also a report of M. gypseum
infection presenting as TDO24 and a further report of M. gyp-
seum  PSO in an immunocompetent host.25 Fingernail infection
was  uncommon in our cohort which included only a single
case  of ﬁngernail M.  gypseum DLSO in a young man  without
apparent risk factors. However, previous studies of M. gypseum
onychomycosis report ﬁngernails being affected in nearly all
cases,  and disease was  usually reported in young women
although no risk factors for infection were suggested.22
Reported cases of M.  canis onychomycosis associated
with immunosuppressive states have been of the common
DLSO  clinical presentation,18 although immunosuppression-
associated onychomycosis usually presents with either PSO
5or  WSO. Paradoxically, there are also reports of M.  canis ony-
chomycosis in immunocompetent individuals presenting as
PSO,16,17 and herein we also report a case of M. canis WSO  in an
immunocompetent patient. These observations suggest that
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ot only is Microsporum onychomycosis uncommon but that
linically  it may  be atypical.
Our study has thrown up further interesting observations.
irstly, direct microscopy demonstrated a dermtophytoma
rom a single patient whose culture subsequently conﬁrmed
o  be M.  canis. This is extremely unusual as M. canis pro-
ucing  dermatophytomas has not been previously reported.
urthermore, dermatophytomas are a poor prognostic sign
nd  generally do not respond favorably to drug therapy as
hey  consist of a densely packed clump of dermatophyte
yphae which are thick-walled and therefore resistant to drug
enetration.26,27 Yet, our patient who had a 14-year history
f  onychomycosis and also suffered from diabetes mellitus
nd  hypertension demonstrated both clinical and mycological
ure  after a standard three-month course of pulse itracona-
ole.  She had previously failed to respond satisfactorily to a
ix-month course of ﬂuconazole 300 mg  weekly but higher
oses  and a longer period of treatment with ﬂuconazole is
sually  required to achieve cure.28 It is also possible that nail
ampling  for mycology from this patient physically removed
he  dermatophytoma which facilitated cure.
Our study also reports the ﬁrst successfully treated cases
f  M.  canis onychomycosis with PDT. In recent years the use
f  PDT has extended to the ﬁeld of antimicrobial chemother-
py,  in vitro studies having demonstrated PDT’s antifungal
ffects.29 PDT is an attractive option as it is minimally inva-
ive  and only locally active and therefore does not cause
ystemic adverse effects or local tissue damage. Furthermore,
nlike antimicrobial drugs there is no potential for the devel-
pment  of resistance. However, in an open trial of 30 patients
ith  T. rubrum onychomycosis, three sessions of PDT given
t  two-week intervals produced only a 43.3% cure rate.30 In
revious  reports of T. rubrum onychomycosis being cured with
DT,  a greater number of PDT sessions were  given at shorter
ntervals.31,32 Our therapy regimen of four treatments given
eekly  may  be the optimal treatment regimen for M. canis
nychomycosis as it achieved clinical and mycological cure
n  both patients treated with this modality.
We report only one case of M. nanun onychomycosis. This
ermatophyte is a rare cause of tinea in humans, but usu-
lly  is present in pigs, its natural reservoir, and it has also
een  reported in cats, dogs and rabbits.33,34 Tinea corporis
an be caused by M.  nanun, but it is an exceptional cause of
nychomycosis. We found a toenail onychomycosis in a 45-
ear-old  woman  with unknown source of infection and risk
actors.35
We  describe the largest case series of Microsporum ony-
homycosis to date. Although the prevalence of Microsporum
nychomycosis in our study is not signiﬁcantly higher than in
ther studies, these cases are notable for the absence of sig-
iﬁcant  risk factors for Microsporum nail infection: only 55%
5/9)  of our cases had concomitant diseases that could pre-
ispose  to infection. Otherwise, other well-recognized risk
actors  associated with Microsporum onychomycosis such as
nderlying immunosuppressive states or contact with dogs
nd  cats were  not diagnosed or reported in any of our cases.
his  signiﬁcant cluster of cases of these rare etiological agents
f  onychomycosis seen at our Institute may  reﬂect an increas-
ng  incidence of Microsporum onychomycosis. The absence of
ny  disease-associated risk factors in almost half of our cases
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suggests that Microsporum sp. may  have greater afﬁnity and
pathogenicity for nail keratin than previously thought.
In  only 18 cases of onychomycosis caused by Microsporum
sp. it has been very difﬁcult to point out special clinical char-
acteristics.
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